Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1Phase 1/2 1

Status

Completed 20Terminated 9Recruiting 5Withdrawn 3Unknown 2Active not recruiting 2

Sponsor Class

OTHER 5

Study Type

Interventional 5

Sponsor

Cancer Type

Other hematologic neoplasm 5Lymphoid 5

Conditions

Multiple Myeloma 32Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Recurrence 4Immunoglobulin Light-chain Amyloidosis 4Neoplasms, Plasma Cell 3Hematologic Neoplasms 3Renal Insufficiency 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Leukemia, Myeloid, Acute 2Breast Neoplasms 2beta-Thalassemia 1Waldenstrom Macroglobulinemia 1Thalassemia 1Plasmablastic Lymphoma 1Peripheral Nervous System Diseases 1Pancreatic Neoplasms 1Neoplasms 1Neoplasm, Residual 1Metastatic Castration-resistant Prostate Cancer 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma 1Leukemia, Plasma Cell 1Leukemia, Biphenotypic, Acute 1Burkitt Lymphoma 1Anemia, Sickle Cell 1Amyloidosis 1Acute-Phase Reaction 1

Interventions

Cyclophosphamide 56fludarabine 30Methotrexate 24blinatumomab 23Dexamethasone 21Cytarabine 21Vincristine 19venetoclax 18Specimen Handling 16fludarabine phosphate 15Whole-Body Irradiation 13Stem Cell Transplantation 12Biopsy 12Tacrolimus 10Mycophenolic Acid 10Immunotherapy, Adoptive 10Daunorubicin 10Thiotepa 9Rituximab 9Prednisone 9Mercaptopurine 9Melphalan 9Magnetic Resonance Spectroscopy 8Doxorubicin 8pegaspargase 7Granulocyte Colony-Stimulating Factor 7Cyclosporine 7olverembatinib 6Mesna 6Inotuzumab Ozogamicin 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Recruiting × Precursor Cell Lymphoblastic Leukemia-Lymphoma × Bortezomib × Clear all
NCT05848687 2026-04-20

TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II

Stanford University

Phase 1/2 Recruiting
90 enrolled
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03590171 2026-03-17

International Study for Treatment of High Risk Childhood Relapsed ALL 2010

Charite University, Berlin, Germany

Phase 2 Recruiting
250 enrolled
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03136146 2026-02-17

Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia

M.D. Anderson Cancer Center

Phase 2 Recruiting
42 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06034561 2025-05-16

Bortezomib-based Regimen for Refractory or Relapsed Acute Lymphoblastic Leukemia

Instituto do Cancer do Estado de São Paulo

Phase 2 Recruiting
50 enrolled
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03643276 2025-04-06

Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017

University Hospital Schleswig-Holstein

Phase 3 Recruiting
5,000 enrolled
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡